T. Rowe Price Associates
STRO icon

T. Rowe Price Associates’s Sutro Biopharma STRO Stock Holding History

T. Rowe Price Associates’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$452K Buy
+13,597
New +$424K ﹤0.01% 2667
2025
Q2 		– Sell
-3,689
Closed -$25K – 3144
2025
Q1 		$25K Buy
3,689
+669
+22% +$10.5K ﹤0.01% 2995
2024
Q4 		$56K Buy
3,020
+394
+15% +$12K ﹤0.01% 2924
2024
Q3 		$91K Hold
2,626
– – ﹤0.01% 2837
2024
Q2 		$77K Buy
2,626
+823
+46% +$32.5K ﹤0.01% 2788
2024
Q1 		$102K Buy
1,803
+358
+25% +$15.8K ﹤0.01% 2781
2023
Q4 		$62K Buy
1,445
+134
+10% +$4.25K ﹤0.01% 2777
2023
Q3 		$46K Buy
1,311
+156
+14% +$6.8K ﹤0.01% 2788
2023
Q2 		$54K Buy
+1,155
New +$57.5K ﹤0.01% 2793
2021
Q2 		– Sell
-2,140
Closed -$487K – 2952
2021
Q1 		$487K Buy
2,140
+43
+2% +$10.2K ﹤0.01% 2383
2020
Q4 		$455K Buy
+2,097
New +$347K ﹤0.01% 2281

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

T. Rowe Price Associates's STRO Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Sutro Biopharma (STRO) in Q2 2026: 13,597 shares worth $452K. The stake represents ﹤0.01% of the portfolio and ranks #2667 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in STRO as recently as Q1 2025.

T. Rowe Price Associates first reported a position in STRO in Q4 2020 and has held it in 11 quarters since. The position peaked at $487K in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • T. Rowe Price Associates held 13,597 shares of Sutro Biopharma worth $452K as of Q2 2026.
  • Sutro Biopharma was a new T. Rowe Price Associates position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2667 holding.
  • T. Rowe Price Associates first reported a position in Sutro Biopharma in Q4 2020 and has held it in 11 quarters since.
  • T. Rowe Price Associates's Sutro Biopharma position peaked at $487K in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.